-

RAFAEL HOLDINGS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Rafael Holdings, Inc. - RFL

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Rafael Pharmaceuticals, Inc. (“Pharma”) to Rafael Holdings, Inc., (“the Company”) (NYSE: RFL). Under the terms of the proposed transaction, Pharma shareholders will receive Holdings Class B common stock amounting to approximately 48% of the currently outstanding capitalization of the company. Additional equity in the company is expected to be issued in connection with anticipated financing and employment agreements, which will reduce the foregoing percentage proportionately. KSF is seeking to determine whether the merger and the process that led to it are adequate and fair to the Company’s shareholders.

If you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn (lewis.kahn@ksfcounsel.com) toll free at any time at 855-768-1857, or visit https://www.ksfcounsel.com/cases/nyse-rfl/ to learn more.

To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com.

Contacts

Kahn Swick & Foti, LLC
Lewis S. Kahn
KSF Managing Partner
lewis.kahn@ksfcounsel.com
855-768-1857

Industry:

Kahn Swick & Foti, LLC

NYSE:RFL
Release Versions
English

Contacts

Kahn Swick & Foti, LLC
Lewis S. Kahn
KSF Managing Partner
lewis.kahn@ksfcounsel.com
855-768-1857

More News From Kahn Swick & Foti, LLC

Olaplex Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Olaplex Holdings, Inc. - OLPX

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Olaplex Holdings, Inc. (NasdaqGS: OLPX) to Henkel AG & Co. KGaA. Under the terms of the proposed transaction, shareholders of Olaplex will receive $2.06 in cash for each share of Olaplex that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequ...

Ultragenyx 72 Hour Deadline Alert: Kahn Swick & Foti, LLC Reminds Investors With Losses In Excess Of $100,000 of Deadline in Class Action Lawsuit Against Ultragenyx Pharmaceutical Inc. - RARE

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Kahn Swick & Foti, LLC (“KSF”) and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until April 6, 2026 to file lead plaintiff applications in a securities class action lawsuit against Ultragenyx Pharmaceutical Inc. (“Ultragenyx” or the “Company”) (NasdaqGS: RARE), if they purchased or otherwise acquired the Company’s securities between August 3, 2023 and December 26, 2025, inclusive (the “Cl...

Calavo Growers Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Calavo Growers, Inc. - CVGW

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Calavo Growers, Inc. (NasdaqGS: CVGW) to Mission Produce, Inc. (NasdaqGS: AVO). Under the terms of the proposed transaction, shareholders of Calavo will receive $14.85 in cash and 0.9790 shares of Mission for each share of Calavo that they own. KSF is seeking to determine whether this consideration a...
Back to Newsroom